Adamas reports positive PII/III data for ADS-5102
This article was originally published in Scrip
Adamas Pharmaceuticals reported final Phase II/III data that show statistically significant improvements versus placebo in levodopa-induced dyskinesia (LID) for Parkinson's disease patients treated with ADS-5102 (Nurelin), an extended-release version of the generic Parkinson's drug amantadine.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.